Inducible expression of the kinin B1 receptor in the endotoxemic heart: mechanisms of des-Arg9bradykinin-induced coronary vasodilation

Authors

  • Peter G McLean,

    Corresponding author
    1. Center for Clinical Pharmacology, Department of Medicine, University College London, WC1E 6JJ
    2. Department of Biochemical Pharmacology, William Harvey Research Institute, St. Bartholomew's Medical College, London, EC1M 6BQ
      Centre for Clinical Pharmacology, The Rayne Institute, UCL, 5 University Street, London WC1E 6JJ. E-mail: p.mclean@ucl.ac.uk
    Search for more papers by this author
  • Mauro Perretti,

    1. Department of Biochemical Pharmacology, William Harvey Research Institute, St. Bartholomew's Medical College, London, EC1M 6BQ
    Search for more papers by this author
  • Amrita Ahluwalia

    1. Center for Clinical Pharmacology, Department of Medicine, University College London, WC1E 6JJ
    Search for more papers by this author

Centre for Clinical Pharmacology, The Rayne Institute, UCL, 5 University Street, London WC1E 6JJ. E-mail: p.mclean@ucl.ac.uk

Abstract

  • We have investigated the role of kinin B1 receptor induction in the endotoxemic rat heart and elucidated the mechanisms underlying B1 receptor-mediated coronary vasodilation. We also investigated the role of these receptors in endotoxin-induced hypotension.

  • Endotoxin treatment induced cardiac B1 receptor mRNA expression and promoted a coronary vasodilation response to des-Arg9bradykinin (DABK; ED50=149.4 pmol, n=9) ex vivo peaking at 6 h. The B1 receptor antagonist des-Arg9-[Leu8]-BK (DALBK, 30 nM) significantly (P<0.05) inhibited the DABK-induced response (pA2=8.4, n=5) whilst HOE140 (B2 receptor antagonist, 10 nM) was inactive (n=4).

  • Removal of the endothelium or infusion with indomethacin (5 μM), but not L-NAME (300 μM) or ODQ (1 μM), inhibited (>85%, P<0.05, n=5) the DABK-induced response. DABK caused a dose-dependent release of the prostacyclin metabolite, 6-keto-PGF1a (Emax=0.3 ng ml−1, n=6).

  • In vitro perfusion of hearts with endotoxin (1 μg ml−1, n=6) or interleukin-1β (5 ng ml−1, n=6) induced B1 receptor mRNA expression and promoted a time-dependent vasodilation response to DABK.

  • Endotoxin treatment (6 h) in vivo promoted a hypotensive response to DABK (ED50=29.7 nmol kg−1, n=10) which was antagonised by DALBK (3–6 nmol kg−1 min−1, P<0.05, n=7). DALBK (3 nmol kg−1 min−1) and des-Arg10HOE140 (B1 receptor antagonist, 30 nmol kg−1 min−1) produced a 5.3% (n=6, P<0.05) and 8.8% (n=5, P<0.05) reversal, respectively, of endotoxin-induced hypotension.

  • In summary, we have shown that in endotoxemia activation of B1 receptors causes coronary vasodilation via endothelial prostacyclin release. Additionally, B1 receptor antagonists partially reversed endotoxin-induced hypotension. Therefore activation of B1 receptors may have a role to play in the vascular changes associated with endotoxemia.

British Journal of Pharmacology (1999) 128, 275–282; doi:10.1038/sj.bjp.0702743

Ancillary